The World Health Organization's situation page for Bundibugyo virus disease, updated on Friday, May 22, 2026, lists roughly 600 suspected cases across the Democratic Republic of the Congo and Uganda and 80 confirmed deaths — the same death-count anchor it published with the May 16 Disease Outbreak Notice that informed the Public Health Emergency of International Concern declaration the next day. [1] The strain-specific vaccine that does not exist is still six to twelve months from the first humans.

The London School of Hygiene & Tropical Medicine, which the WHO consults on emergency-use protocols, told its own newsroom on May 20 that a Bundibugyo-strain candidate could enter a Phase I trial in six to twelve months. [2] Scientific American, on the same day, confirmed that several teams — including Sabin and CEPI-funded variants on the rVSV platform, plus at least one mRNA approach — have preclinical work in hand but no licensed product. [3] Ervebo, the licensed Zaire-strain vaccine that ended the 2018-19 DRC outbreak, does not cover Bundibugyo. The paper's Day Three feature put the gap plainly. Friday adds the calendar.

The calendar is the policy. Bundibugyo virus has caused two prior outbreaks in two decades — Uganda 2007, Isiro DRC 2012 — both small enough that the priority-setting committees at WHO, Gavi and CEPI funded other pathogens. A May 19 WHO vaccine-options consultation confirmed by Gavi is the moment that decision is being relitigated in public. [4] Phase I is not deployment. The 2014-16 West Africa epidemic killed more than 11,000 people before Ervebo's ring-vaccination trial began in Guinea in March 2015, and the vaccine did not receive WHO prequalification until November 2019.

Genomic analysis published on virological.org on May 18 confirmed the May 2026 outbreak is a new spillover event, not a continuation of the 2007 or 2012 lineages. [5] The same day, the Africa Centres for Disease Control declared a Public Health Emergency of Continental Security — the continent-level escalation Bunia health officials had requested since the WHO PHEIC. [6] The Africa CDC declaration is separate from the WHO PHEIC and does not borrow its authorities; it does signal that Jean Kaseya's "panic mode" line from the May 17 Africa CDC briefing reached the African Union political layer.

The paper holds two frames against each other on Friday. The first is procedural: a WHO declaration on May 17, an Africa CDC declaration on May 18, a Bangladesh-style probe-with-names on a parallel measles procurement track, a CDC interim final rule widening Title 42 to lawful permanent residents on May 22 — the institutional layer is moving. The second frame is operational: no licensed countermeasure exists for the strain doing the killing, and the trial that produces one starts at the earliest in late 2026. The Australian CDC's first situation report on May 18 said it plainly — "no licensed vaccine or specific therapeutics" — and ranked the risk to Australia as low only because the strain has so far stayed inside two countries whose borders close in directions Australia does not face. [7]

Six to twelve months is not a number that comforts a treatment-center clinician in Bunia. It is a number that requires Sabin, CEPI, MSD and Merck to publish manufacturing-readiness timelines now, so that emergency-use authorization can compress what the cold chain and the case-investigation forms cannot. The Australian sitrep notes the WHO advice against border closures, and the U.S. CDC has gone the other way; the case for the vaccine calendar is the institutional escape from the border-closure debate.

The Bunia treatment center keeps running on supportive care — fluids, electrolytes, anti-emetics, the same regimen that has kept the Bundibugyo-strain case-fatality rate between 30% and 50% across all three documented outbreaks since 2007. The genomic note from virological.org said the strain "remains distinct" from earlier outbreaks. The treatment regimen, twenty years on, does not.

Friday is the day the vaccine clock acquires a number. It is not a number that closes a wound. It is a number that says when the next outbreak — and there will be one — might land on a different curve.

-- NORA WHITFIELD, Chicago